These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 4215480)
21. Enzyme replacement therapy for Fabry disease: morphologic and histochemical changes in the urinary sediments. Utsumi K; Mitsuhashi F; Asahi K; Sakurazawa M; Arii K; Komaba Y; Katsumata T; Katsura K; Kase R; Katayama Y Clin Chim Acta; 2005 Oct; 360(1-2):103-7. PubMed ID: 16112661 [TBL] [Abstract][Full Text] [Related]
22. [Fabry disease: systemic deposition of a glycolipid]. Sela BA; Pavlotsky F; Trau H; Kaplan B; Polak-Charcon S; Engelberg S Harefuah; 1994 Sep; 127(5-6):157-60, 215. PubMed ID: 7995582 [TBL] [Abstract][Full Text] [Related]
23. Detection and properties of an acid -galactosidase (ceramidetrihexosidase) in normal human urine. Rietra PJ; Tager JM; Borst P Biochim Biophys Acta; 1972 Oct; 279(3):436-45. PubMed ID: 5082511 [No Abstract] [Full Text] [Related]
24. Fabry disease: case report with emphasis on enzyme replacement therapy and possible future therapeutic options. Möhrenschlager M; Pontz BF; Lanzl I; Podskarbi T; Henkel V; Ring J J Dtsch Dermatol Ges; 2007 Jul; 5(7):594-7. PubMed ID: 17610610 [TBL] [Abstract][Full Text] [Related]
25. Angiokeratomas, Fabry disease and enzyme replacement therapy: still a challenge. Möhrenschlager M; Henkel V; Ring J Br J Dermatol; 2005 Jan; 152(1):177-8; author reply 178-9. PubMed ID: 15656825 [No Abstract] [Full Text] [Related]
26. A microtechnique for quantitative measurements of acid hydrolases in fibroblasts. Its application in diagnosis of Fabry disease and enzyme replacement studies. Hasholt L; Sørensen SA Clin Chim Acta; 1984 Sep; 142(2):257-61. PubMed ID: 6094040 [No Abstract] [Full Text] [Related]
27. Angiokeratoma corporis diffusum with alpha-L-fucosidase deficiency. Epinette WW; Norins AL; Drew AL; Zeman W; Patel V Arch Dermatol; 1973 May; 107(5):754-7. PubMed ID: 4634000 [No Abstract] [Full Text] [Related]
28. Fabry disease: correction of the enzymatic deficiency by renal transplantation. Desnick RJ; Allen KY; Simmons RL; Woods JE; Anderson CF; Najarian JS; Krivit W Birth Defects Orig Artic Ser; 1973 Mar; 9(2):88-96. PubMed ID: 4215479 [No Abstract] [Full Text] [Related]
29. Enzyme therapy in Fabry's disease by renal transplantation. Desnick RJ; Raman M; Allen KY; Desnick SJ; Simmons RL; Anderson CF; Woods JE; Najarian JS; Krivit W Proc Clin Dial Transplant Forum; 1972; 2():27-35. PubMed ID: 4219812 [No Abstract] [Full Text] [Related]
31. Enzymatic corrections for cells derived from Fabry disease patients by a recombinant adenovirus vector. Ohsugi K; Kobayashi K; Itoh K; Sakuraba H; Sakuragawa N J Hum Genet; 2000; 45(1):1-5. PubMed ID: 10697955 [TBL] [Abstract][Full Text] [Related]
32. Purification and characterization of human alpha-galactosidase A expressed in insect cells using a baculovirus vector. Chen Y; Jin M; Goodrich L; Smith G; Coppola G; Calhoun DH Protein Expr Purif; 2000 Nov; 20(2):228-36. PubMed ID: 11049747 [TBL] [Abstract][Full Text] [Related]
33. beta-Galactosidase and neuraminidase deficiency associated with angiokeratoma corporis diffusum. Ishibashi A; Tsuboi R; Shinmei M Arch Dermatol; 1984 Oct; 120(10):1344-6. PubMed ID: 6435542 [TBL] [Abstract][Full Text] [Related]
34. Fabry disease manifesting as chronic uveitis--treated with enzyme replacement therapy. Shen YD; Yang CM; Huang JS Eye (Lond); 2007 Mar; 21(3):431-2. PubMed ID: 16858434 [No Abstract] [Full Text] [Related]
36. Expression and characterization of glycosylated and catalytically active recombinant human alpha-galactosidase A produced in Pichia pastoris. Chen Y; Jin M; Egborge T; Coppola G; Andre J; Calhoun DH Protein Expr Purif; 2000 Dec; 20(3):472-84. PubMed ID: 11087687 [TBL] [Abstract][Full Text] [Related]
37. Enzyme replacement therapy in Fabry disease: towards a better understanding of the implications of antibody formation and dose. Hollak CE; Vedder AC; Winchester B; Aerts JM; Breunig F Mol Genet Metab; 2008 Dec; 95(4):239-40. PubMed ID: 18842432 [No Abstract] [Full Text] [Related]
38. Heterozygote detection in Fabry disease utilizing multiple enzyme activities. Sheth KJ; Good TA; Murphy JV Am J Med Genet; 1981; 10(2):141-6. PubMed ID: 6274191 [TBL] [Abstract][Full Text] [Related]
39. Quantitative evaluation of sphingolipids using delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry with sphingosylphosphorylcholine as an internal standard. Practical application to cardiac valves from a patient with Fabry disease. Fujiwaki T; Tasaka M; Takahashi N; Kobayashi H; Murakami Y; Shimada T; Yamaguchi S J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):97-102. PubMed ID: 16431168 [TBL] [Abstract][Full Text] [Related]
40. Role of lysosomal acid ceramidase in the metabolism of ceramide in human skin fibroblasts. Chen WW; Moser AB; Moser HW Arch Biochem Biophys; 1981 May; 208(2):444-55. PubMed ID: 7259198 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]